CHEMOMAB THERAPEUTICS LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.67 USD | +4.70% |
|
+1.53% | +31.37% |
| 10/04 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
| 07/03 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 9.09M 758M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M -1.25B | Net income 2025 * | -22M -1.84B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-8.53
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Chemomab Therapeutics Ltd.
More recommendations
More press releases
| 1 day | +4.70% | ||
| 1 week | +1.53% | ||
| Current month | -13.99% | ||
| 1 month | -13.12% | ||
| 3 months | +24.07% | ||
| 6 months | -9.46% | ||
| Current year | +31.37% |
1 week
0.62
0.69
1 month
0.580.81
Current year
0.460.88
1 year
0.421.89
3 years
0.4232.75
5 years
0.4279.00
10 years
0.4279.00
| Managers | Title | Age | Since |
|---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 22/11/22 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 01/20/01 |
| Chief Tech/Sci/R&D Officer | 56 | 14/22/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 01/20/01 |
Nissim Darvish
CHM | Chairman | 59 | 16/21/16 |
Claude Nicaise
BRD | Director/Board Member | 71 | 16/21/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 0.67 | +4.70% | 18 266 |
| 26/24/26 | 0.6399 | -2.90% | 23,560 |
| 25/24/25 | 0.659 | -1.64% | 11,541 |
| 24/24/24 | 0.67 | 0.00% | 3,426 |
| 23/24/23 | 0.67 | +1.53% | 7,157 |
Delayed Quote Nasdaq, April 29, 2024 at 11:36 pm IST
More quotes
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Calendar
09/05/2024
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.6399
USD
Average target price
7
USD
Spread / Average Target
+993.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +31.37% | 9.09M | |
| -2.85% | 103B | |
| +1.58% | 95.28B | |
| +1.46% | 22.15B | |
| -16.14% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.28% | 16.05B | |
| +5.54% | 13.68B | |
| +33.04% | 12.17B |
- Stock Market
- Equities
- CMMB Stock
